Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

Key Findings

Real-world results vs. trial results: the gap is real, but explainable 📊

• A narrative review comparing 127 randomized trials with 26 real-world studies found that people with type 2 diabetes lost 4.7–10.5 kg in practice versus higher estimates in trials — largely because only 13% of semaglutide users and 26% of tirzepatide users actually reached the target dose.
• Among people without diabetes who stayed on the drug at full dose, real-world weight loss closely matched trial results (semaglutide: ~14% vs. 14.9% in trials).

Semaglutide protects the liver beyond weight loss — here's the mechanism 🔬

• A new study found that GLP-1 receptors on liver sinusoidal endothelial cells — not fat loss — are a key pathway through which semaglutide reduces liver damage in metabolic-associated steatohepatitis.
• The finding reframes semaglutide as having direct hepatoprotective effects, separate from its appetite-suppressing action, which matters for patients whose liver disease may not fully respond to weight loss alone.

Tirzepatide cut heart failure risk in women with obesity-related HFpEF 💙

• A prespecified sex-based analysis of the SUMMIT trial found that tirzepatide reduced cardiovascular death or worsening heart failure in women with obesity-related heart failure with preserved ejection fraction — a condition where women outnumber men.
• The results were consistent with the overall trial benefit, suggesting the drug's effects aren't diluted by the sex differences in fat distribution and disease biology that make HFpEF harder to treat in women.

GLP-1 drugs in Alzheimer's mouse models: no effect on the disease itself 🐭

• Semaglutide and tirzepatide both lowered body weight and improved glucose tolerance in 5xFAD mice — a standard Alzheimer's model — but neither drug changed memory, amyloid plaque buildup, or brain inflammation after 2 or 4 months of treatment.
• The result is a cautionary note for the growing excitement around GLP-1 drugs and neurodegeneration: metabolic benefits in the brain don't automatically translate to disease modification.

GLP-1 drugs linked to menstrual changes — the signal varies by drug 🩸

• An analysis of FDA adverse event reports from women aged 12–55 found that semaglutide was associated with heavy menstrual bleeding, irregular bleeding, menstrual clots, and reduced or absent cycles. Tirzepatide showed signals for irregular and clot-related bleeding. Liraglutide produced no significant signals.
• The study is pharmacovigilance data — it captures reports, not confirmed causation — but the drug-specific pattern suggests these aren't random noise.

GLP-1 prescriptions from online sellers: minimal clinical oversight found 💻

• A secret shopper study published in JAMA examined the process of obtaining GLP-1 drugs from online sellers and found the prescription process involved limited clinical engagement.
• The findings raise direct questions about safety screening, appropriate patient selection, and dose monitoring when these drugs are dispensed outside traditional clinical settings.